Antitumor activity of the novel pyridine derivative

• Main Authors: Ekaterina V. Blinova (Author), Anna V. Epishkina (Author), Oksana M. Tumutolova (Author), Olga N. Deryabina (Author), Sofia Ya. Skachilova (Author), Mihail Yu. Kudriavtsev (Author), Evgenia V. Shikh (Author), Olga S. Vavilova (Author), Yulia S. Gilevskaya (Author), Gordey V. Brykin (Author), Anna A. Makhrova (Author), Dmitry S. Blinov (Author)
• Format: Book
• Published: Belgorod National Research University, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Introduction: The study aim was to explore a toxicological property and antitumor action of the novel pyridine derivative LHT-17-19 in cell culture and on experimental models of lung cancer in mice. Materials and methods: The study was performed on male and female ICR(CD-1), male BALB/c, male BALB/c nu/nu mice. Pyridine derivative (LHT-17-19) was studied as water-soluble pharmaceutical substance. Acute toxicity was evaluated in groups of 5 animals, and the results were analyzed by Finney. Antitumor and antimetastatic activity was studied in syngeneic and xenograft models of lung cancer in mice. Results and discussion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with GOST 12.1.007-76. The substance demonstrated an antitumor and antimetastatic property in mice with syngeneic tumor Lewis lung carcinoma as well as on the heterotopic tumor model of non-small cell lung cancer in humanized animals. Conclusion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with WHO recommendation. LHT-17-19 exerts antitumor and antimetastatic property on both syngeneic and patient-derived lung cancer xenograft murine models. Graphical abstract

Item Description

10.3897/rrpharmacology.8.89997
2658-381X